VivoSeq
Other

Reproductive Disorder

1

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Reproductive Disorder is an early-stage landscape with 1 program across 1 company. The most active players are Stephanie B. Seminara, MD.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Stephanie B. Seminara, MD

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Kisspeptin 112-121

Stephanie B. Seminara, MD

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
Completed·—·Phase 1·NCT05633966·13 enrolled
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Recruiting·SStephanie B. Seminara, MD·Phase 1·NCT07224490·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)